Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Submission of Matters to a Vote of Security Holders

Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07

Submission of Matters to a Vote of Security
Holders.

On June1, 2017, Aradigm Corporation (the Company) convened its
Annual Meeting of Shareholders (the Meeting). Five proposals were
presented and voted on and the results for the five proposals
were reported at the Meeting. Set forth below are the results
reported at the Meeting for proposals 1, 2, 3, 4 and 5.

Proposal 1 Election of David Bell, Igor Gonda, Frederick Hudson,
John M. Siebert and Virgil D. Thompson as directors to serve
until the next annual meeting of shareholders and until their
successors are duly elected and qualified.

All of the following five nominees for directors were elected to
hold offices until the next annual meeting of shareholders and
until their successors are elected:

Nominee

For Withheld Non-votes

David Bell

9,601,780 265,152 2,166,469

Igor Gonda

9,759,101 107,831 2,166,469

Frederick Hudson

9,251,396 615,536 2,166,469

John M. Siebert

9,251,428 615,504 2,166,469

Virgil D. Thompson

9,238,838 628,094 2,166,469

The five nominees received the highest number of For votes from
the holders of votes of shares present in person or represented
by proxy and entitled to vote at the Meeting on the election of
directors. Withheld votes and broker non-votes have no effect on
the outcome of the election of directors.

Proposal 2 Approval of an amendment to Aradigms Employee Stock
Purchase Plan to increase the aggregate number of shares of
Common Stock authorized for issuance under such plan by 200,000
shares.

For:

9,753,705

Against:

109,681

Abstain:

3,546

Non-votes:

2,166,469

Proposal 2 received For votes from the holders of at least a
majority of the outstanding shares of common stock present either
in person or by proxy and entitled to vote at the Meeting.
Proposal 2 therefore passed.

1

Proposal 3 Approval of an amendment to Aradigms 2015 Equity
Incentive Plan to increase the aggregate number of shares of
Common Stock authorized for issuance under such plan by
2,500,000.

For:

9,433,716

Against:

431,199

Abstain:

2,017

Non-votes:

2,166,469

Proposal 3 received For votes from the holders of at least a
majority of the outstanding shares of common stock present either
in person or by proxy and entitled to vote at the Meeting.
Proposal 3 therefore passed.

Proposal 4 Ratification of the selection of OUM Co. LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017.

For:

11,958,488

Against:

67,701

Abstain:

7,212

Non-votes:

Proposal 4 received For votes from the holders of at least a
majority of the outstanding shares of common stock present either
in person or by proxy and entitled to vote at the Meeting.
Proposal 4 therefore passed.

Proposal 5 Non-binding advisory vote approving the executive
compensation of the Companys named executive officers.

For:

9,399,239

Against:

465,963

Abstain:

1,730

Non-votes:

2,166,469

Proposal 5 received For votes from the holders of at least a
majority of the outstanding shares of common stock present either
in person or by proxy and entitled to vote at the Meeting.
Proposal 5 therefore passed.

2


About Aradigm Corporation (NASDAQ:ARDM)

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

An ad to help with our costs